Guidance for the prevention and management of adverse events in patients receiving dinutuximab beta therapy

The guidelines for the prevention and management of adverse events in patients receiving dinutuximab beta therapy provide recommendations for assessing the risk of development, prevention and management of adverse events.

1. Voeller J., Sondel P.M. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2019;41(3):163–9. doi: 10.1097/MPH.0000000000001369.

2. Neuroblastoma. Clinical guidelines. ID: 78_2. [Electronic resource]: URL: https://cr.minzdrav.gov.ru/preview-cr/78_2 (appeal date 20.03.2025). (In Russ.)].

3. Qarziba (dinutuximab beta) Summary of Product Characteristics (28/01/2020). [Electronic resource]: URL: https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en.pdf. Accessed Dec 2020.

4. Hoy S.M. Dinutuximab: A Review in High-Risk Neuroblastoma. Target Oncol. 2016;11(2):247–53. doi: 10.1007/s11523-016-0420-2.

5. Mastrangelo S., Rivetti S., Triarico S., Romano A., Attinà G., Maurizi P., Ruggiero A. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. Int J Mol Sci. 2021;22(23):12648. doi: 10.3390/ijms222312648.

6. Nazha B., Inal C., Owonikoko T.K. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000. doi: 10.3389/fonc.2020.01000.

7. Parsons K., Bernhardt B., Strickland B. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Ann Pharmacother. 2013;47(2):210–8. doi: 10.1345/aph.1R353.

8. Shamanskaya T.V., Kachanov D.Yu., Ivanov N.S., Rabaeva L.L., Yadgarov M.Ya., Zatsarinnaya O.S., Utalieva D.T., Litvinov D.V., Rumyantsev A.G., Novichkova G.A. Tolerability and toxicity of induction chemoimmunotherapy with dinutuximab beta in newly diagnosed patients with high-risk neuroblastoma. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2024;23(1):108–18. (In Russ.)].

9. Kulyova S.A., Varfolomeeva S.R., Kirgizov K.I., Prosekina E.A., Romantsova O.M., Gorbunova T.V. A phase III, multicenter, open-label study of dinutuximab beta without/with chemotherapy at the investigator’s choice in patients under 18 years old with bone and soft tissue sarcomas with positive expression GD2 and disease progression during the fi rst-line chemotherapy. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology. 2024;11(2):12–20. (In Russ.)].

10. State Register of Medicines of the Ministry of Health of the Russian Federation, 2022. [Electronic resource]: URL: https://web.archive.org/web/20221227085254/https://grls.rosminzdrav.ru/Default.aspx. (appeal date 27.02.2025). (In Russ.)].

11. Faseeva N.D., Kuleva S.A., Ivanova S.V., Gumbatova E.D., Senchurov E.M., Subora А.Yu., Mikhailova E.M., Gogun A.A., Izmozherova R.I., Borokshinova K.M. Passive immunotherapy experience in patients with high-risk neuroblastoma. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology. 2019;6(4):33–9. (In Russ.)].

12. Ladenstein R., Pötschger U., Valteau-Couanet D., Luksch R., Castel V., Yaniv I., Laureys G., Brock P., Michon J.M., Owens C., Trahair T., Chan G.C.F., Ruud E., Schroeder H., Beck Popovic M., Schreier G., Loibner H., Ambros P., Holmes K., Castellani M.R., Gaze M.N., Garaventa A., Pearson A.D.J., Lode H.N. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617–29. doi: 10.1016/S1470-2045(18)30578-3.

13. Ladenstein R., Pötschger U., Valteau-Couanet D., Gray J., Luksch R., Balwierz W., Castel V., Ash S., Beck-Popovic M., Laureys G., Chi Fung Chan G., Ruud E., Vettenranta K., Owens C., Schroeder H., Loibner H., Ambros P.F., Sarnacki S., Boterberg T., Lode H.N. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line highrisk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. J Clin Oncol. 2019;37:10013.

14. Ladenstein R., Pötschger U., Valteau-Couanet D., Luksch R., Castel V., Ash S., Laureys G., Brock P., Michon J.M., Owens C., Trahair T., Chi Fung Chan G., Ruud E., Schroeder H., Beck-Popovic M., Schreier G., Loibner H., Ambros P., Holmes K., Castellani M.R., Gaze M.N., Garaventa A., Pearson A.D.J., Lode H.N. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel). 2020;12(2):309. doi: 10.3390/cancers12020309.

15. Balaguer J., García Hidalgo L., Hladun R., Márquez Vega C., Pérez Alonso V. Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma. Target Oncol. 2023;18(1):77–93. doi: 10.1007/s11523-022-00930-w.

16. Barone G., Barry A., Bautista F., Brichard B., Defachelles A.S., Herd F., Manzitti C., Reinhardt D., Rubio P.M., Wieczorek A., van Noesel M.M. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance. Paediatr Drugs. 2021;23(6):537–48. doi: 10.1007/s40272-021-00469-9.

17. Wieczorek A., Manzitti C., Garaventa A., Gray J., Papadakis V., Valteau-Couanet D., Zachwieja K., Poetschger U., Pribill I., Fiedler S., Ladenstein R., Lode H.N. Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers (Basel). 2022;14(8):1919. doi: 10.3390/cancers14081919.

18. Olgun N., Cecen E., Ince D., Kizmazoglu D., Baysal B., Onal A., Ozdogan O., Guleryuz H., Cetingoz R., Demiral A., Olguner M., Celik A., Kamer S., Ozer E., Altun Z., Aktas S. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience. Front Oncol. 2022;12:1041443. doi: 10.3389/fonc.2022.1041443.

19. Wieczorek A., Zaniewska-Tekieli A., Ehlert K., Pawinska-Wasikowska K., Balwierz W., Lode H. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma. Front Oncol. 2023;13:1082771. doi: 10.3389/fonc.2023.1082771.

20. Lang P., Flaadt T., Ebinger M., Schlegel P., Lode H., Ladenstein R., Lang A.M., Ambross P., Schaefer J., Fuchs J., Loibner H., Schwinger W., Handgretinger R. Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR. Cancer Immunol Res. 2019;7(2 Suppl):Abstract nr A013.

21. Siebert N., Eger C., Seidel D., Jüttner M., Zumpe M., Wegner D., Kietz S., Ehlert K., Veal G.J., Siegmund W., Weiss M., Loibner H., Ladenstein R., Lode H.N. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs. 2016;8(3):604–16. doi: 10.1080/19420862.2015.1130196.

22. Siebert N., Troschke-Meurer S., Marx M., Zumpe M., Ehlert K., Gray J., Garaventa A., Manzitti C., Ash S., Klingebiel T., Beck J., Castel V., Valteau-Couanet D., Loibner H., Ladenstein R., Lode H.N. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers (Basel). 2018;10(10):387. doi: 10.3390/cancers10100387.

23. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: 27 November 2017. U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute. [Electronic resource]: URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

24. Amoroso L., Fagioli F., Tondo A., Conte M., Badino C., Di Cataldo A., Viscardi E., De Leonardis F., De Ioris M.A., Luksch R. Strategies to manage the adverse eff ects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review. Support Care Cancer. 2025;33(3):153. doi: 10.1007/s00520-024-09135-5.

25. Keyel M.E., Reynolds C.P. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 2018;13:1–12. doi: 10.2147/BTT.S114530.

26. Lammie G., Cheung N., Gerald W., Rosenblum M., Cordoncardo C. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas – an immunohistochemical study. Int J Oncol. 1993;3(5):909–15. doi: 10.3892/ijo.3.5.909.

27. Lode H.N., Valteau-Couanet D., Gray J., Luksch R., Wieczorek A., Castel V., Ash S., Laureys G., Papadakis V., Owens C., Garaventa A., Manzitti C., Siebert N., Troschke-Meurer S., Glogova E., Poetschger U., Ladenstein R.L. Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial. J Clin Oncol. 2019:15_suppl:10014. doi: 10.1200/JCO.2019.37.15_ suppl.1001.

28. Brennan F.R., Morton L.D., Spindeldreher S., Kiessling A., Allenspach R., Hey A., Muller P.Y., Frings W., Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2(3):233–55. doi: 10.4161/mabs.2.3.11782.

29. Blom T., Lurvink R., Aleven L., Mensink M., Wolfs T., Dierselhuis M., van Eijkelenburg N., Kraal K., van Noesel M., van Grotel M., Tytgat G. Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Front Oncol. 2021;10:601076. doi: 10.3389/fonc.2020.601076.

30. Andreeva N.A., Bezdolnova E.O., Kachanov D.Yu., Smirnova A.B., Teleshova M.V., Utalieva D.T., Khamin I.G., Shamanskaya T.V. Ophthalmic toxicity of anti-GD2 immunotherapy (dinutuximab beta) in a patient with highrisk neuroblastoma: a case report and literature review. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatrics. Journal named after G.N. Speransky. 2021;100(3):248–57. (In Russ.)].

31. Papadakis V., Kelaidi C., Zisaki K., Antoniadi K., Pitsoulakis G., Polychronopoulou S. Dinutuximab beta-related severe neurotoxicity: Resolution with the use of plasmapheresis. Pediatr Blood Cancer. 2022;69(4):e29465. doi: 10.1002/pbc.29465.

32. Xu J., Xie L., Sun X., Guo W. Irinotecan-Induced Diarrhea during a Protracted Administration Schedule for Pediatric Sarcomas – Mechanisms and Clinical Applications. Clin Oncol. 2022;7:1953. ISSN: 2474-1663.

33. 33 Stein A., Voigt W., Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. doi: 10.1177/1758834009355164.

34. Pappo A.S., Lyden E., Breitfeld P., Donaldson S.S., Wiener E., Parham D., Crews K.R., Houghton P., Meyer W.H.; Childrenʼs Oncology Group. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Childrenʼs Oncology Group. J Clin Oncol. 2007;25(4):362–9. doi: 10.1200/JCO.2006.07.1720.

35. Wagner L.M., McAllister N., Goldsby R.E., Rausen A.R., McNallKnapp R.Y., McCarville M.B., Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48(2):132–9. doi: 10.1002/pbc.20697.

36. European Medicines Agency (EMA). European Public Assessment Report (EPAR) for dinutuximab beta (Apeiron): EMA/263814/2017, fi rst published 15 May 2017.